IPDx Diagnostics OÜ

Active Registry code 14261017 OÜ Tallinn Registered 17 May 2017
Compare

IPDx Diagnostics OÜ is a OÜ based in Tallinn, registry code 14261017, status: active. Main activity: Research and experimental development on biotechnology. According to EMTA, turnover for Q3 2026 was €0 with employees.

Turnover
0 €
State taxes
—
Labour taxes
—
Employees
—

Q3 2026 · data from the Tax and Customs Board (EMTA)

Position in the industry Scientific research and development · EMTAK 72

  • Revenue · 2025 0 €
    industry median 0 € · companies in the industry: 1 073

Taxes and turnover

Q4 2023 – Q3 2026
Turnover, € Q3 2026: 0 € · industry median 14 442 € · above 2% of the industry
05 00010 00015 00020 000Q4 2023 Company: 0 € Industry median: 15 375 €Q4·23Q1 2024 Company: 0 € Industry median: 14 938 €Q2 2024 Company: 0 € Industry median: 14 999 €Q2·24Q3 2024 Company: 0 € Industry median: 11 985 €Q4 2024 Company: 0 € Industry median: 16 752 €Q4·24Q1 2025 Company: 0 € Industry median: 15 203 €Q2 2025 Company: 0 € Industry median: 14 420 €Q2·25Q3 2025 Company: 0 € Industry median: 13 763 €Q4 2025 Company: 0 € Industry median: 13 976 €Q4·25Q1 2026 Company: 0 € Industry median: 14 268 €Q2 2026 Company: 0 € Industry median: 14 545 €Q2·26Q3 2026 Company: 0 € Industry median: 14 442 €Q3·2605 00010 00015 00020 000Q4 2024 Company: 0 € Industry median: 16 752 €Q1 2025 Company: 0 € Industry median: 15 203 €Q1·25Q2 2025 Company: 0 € Industry median: 14 420 €Q3 2025 Company: 0 € Industry median: 13 763 €Q3·25Q4 2025 Company: 0 € Industry median: 13 976 €Q1 2026 Company: 0 € Industry median: 14 268 €Q1·26Q2 2026 Company: 0 € Industry median: 14 545 €Q3 2026 Company: 0 € Industry median: 14 442 €Q3·26
  • Company
  • Industry median

Industry: Scientific research and development (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Figures by quarter
Quarter Turnover, € State taxes, € Labour taxes, € Employees
Q3 2026 — — — —
Q2 2026 — — — —
Q1 2026 — — — —
Q4 2025 — — — —
Q3 2025 — — — —
Q2 2025 — — — —
Q1 2025 — — — —
Q4 2024 — — — —
Q3 2024 — — — —
Q2 2024 — — — —
Q1 2024 — — — —
Q4 2023 — — — —
Q3 2023 — — — —
Q2 2023 — — — —
Q1 2023 — — — —
Q4 2022 — 7 090 7 476 —
Q3 2022 6 760 11 126 11 786 —
Q2 2022 30 100 24 738 26 119 5
Q1 2022 67 770 28 361 25 988 8

Financials by year

2017 – 2025
Revenue, € 2025: 0 € · industry median 0 € · above 5% of the industry
05 00010 00015 00020 0002017 Company: — Industry median: —20172018 Company: — Industry median: —20182019 Company: 14 179 € Industry median: 0 €20192020 Company: 454 € Industry median: 150 €20202021 Company: 20 000 € Industry median: 0 €20212022 Company: 6 000 € Industry median: 103 €20222023 Company: 0 € Industry median: 76 €20232024 Company: 0 € Industry median: 0 €20242025 Company: 0 € Industry median: 0 €202505 00010 00015 00020 0002018 Company: — Industry median: —2019 Company: 14 179 € Industry median: 0 €20192020 Company: 454 € Industry median: 150 €2021 Company: 20 000 € Industry median: 0 €20212022 Company: 6 000 € Industry median: 103 €2023 Company: 0 € Industry median: 76 €20232024 Company: 0 € Industry median: 0 €2025 Company: 0 € Industry median: 0 €2025
  • Company
  • Industry median

Industry: Scientific research and development (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Net profit, € thousand 2025: -1 458 € · −4.2% vs 2024 · industry median 0 € · above 19% of the industry
-300-200-10001002017 Company: — Industry median: —20172018 Company: — Industry median: —20182019 Company: -139 933 € Industry median: 3 €20192020 Company: -177 258 € Industry median: 28 €20202021 Company: -285 629 € Industry median: 1 €20212022 Company: -119 326 € Industry median: 0 €20222023 Company: -33 529 € Industry median: 0 €20232024 Company: -1 399 € Industry median: 0 €20242025 Company: -1 458 € Industry median: 0 €2025-300-200-10001002018 Company: — Industry median: —2019 Company: -139 933 € Industry median: 3 €20192020 Company: -177 258 € Industry median: 28 €2021 Company: -285 629 € Industry median: 1 €20212022 Company: -119 326 € Industry median: 0 €2023 Company: -33 529 € Industry median: 0 €20232024 Company: -1 399 € Industry median: 0 €2025 Company: -1 458 € Industry median: 0 €2025
  • Company
  • Industry median

Industry: Scientific research and development (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Net profit margin, % 2022: -1 988.8 % · −560.6 pp vs the year before · industry median 17.7 % · above 2% of the industry
-2 000-1 500-1 000-50005002017 Company: — Industry median: —20172018 Company: — Industry median: —20182019 Company: -986.9 % Industry median: 12.7 %20192020 Company: — Industry median: 23.8 %20202021 Company: -1 428.1 % Industry median: 25.1 %20212022 Company: -1 988.8 % Industry median: 17.7 %20222023 Company: — Industry median: 16.8 %20232024 Company: — Industry median: 15.8 %20242025 Company: — Industry median: 13.5 %2025-2 000-1 500-1 000-50005002018 Company: — Industry median: —2019 Company: -986.9 % Industry median: 12.7 %20192020 Company: — Industry median: 23.8 %2021 Company: -1 428.1 % Industry median: 25.1 %20212022 Company: -1 988.8 % Industry median: 17.7 %2023 Company: — Industry median: 16.8 %20232024 Company: — Industry median: 15.8 %2025 Company: — Industry median: 13.5 %2025
  • Company
  • Industry median

Industry: Scientific research and development (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Assets, € thousand 2025: 382 189 € · −0.6% vs 2024
02004006008002017 Company: —20172018 Company: —20182019 Company: 400 700 €20192020 Company: 706 697 €20202021 Company: 446 140 €20212022 Company: 419 222 €20222023 Company: 386 373 €20232024 Company: 384 650 €20242025 Company: 382 189 €202502004006008002018 Company: —2019 Company: 400 700 €20192020 Company: 706 697 €2021 Company: 446 140 €20212022 Company: 419 222 €2023 Company: 386 373 €20232024 Company: 384 650 €2025 Company: 382 189 €2025
Equity, € thousand 2025: 162 716 € · −0.9% vs 2024
02004006008002017 Company: —20172018 Company: —20182019 Company: 54 026 €20192020 Company: 655 754 €20202021 Company: 370 125 €20212022 Company: 249 102 €20222023 Company: 165 574 €20232024 Company: 164 175 €20242025 Company: 162 716 €202502004006008002018 Company: —2019 Company: 54 026 €20192020 Company: 655 754 €2021 Company: 370 125 €20212022 Company: 249 102 €2023 Company: 165 574 €20232024 Company: 164 175 €2025 Company: 162 716 €2025
Employees 2025: 0 · industry median 1 · above 2% of the industry
02462017 Company: 0 Industry median: —20172018 Company: 0 Industry median: 120182019 Company: 1 Industry median: 120192020 Company: 3 Industry median: 120202021 Company: 6 Industry median: 120212022 Company: 3 Industry median: 220222023 Company: 0 Industry median: 120232024 Company: 0 Industry median: 120242025 Company: 0 Industry median: 1202502462018 Company: 0 Industry median: 12019 Company: 1 Industry median: 120192020 Company: 3 Industry median: 12021 Company: 6 Industry median: 120212022 Company: 3 Industry median: 22023 Company: 0 Industry median: 120232024 Company: 0 Industry median: 12025 Company: 0 Industry median: 12025
  • Company
  • Industry median

Industry: Scientific research and development (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Financials by year
Year Revenue, € Net profit, € Labour costs, € Assets, € Equity, € Employees
2025 0 -1 458 0 382 189 162 716 0
2024 0 -1 399 0 384 650 164 175 0
2023 0 -33 529 0 386 373 165 574 0
2022 6 000 -119 326 117 241 419 222 249 102 3
2021 20 000 -285 629 225 343 446 140 370 125 6
2020 454 -177 258 96 113 706 697 655 754 3
2019 14 179 -139 933 35 861 400 700 54 026 1
2018 — — — — — 0
2017 — — — — — 0

Figures from the company’s own (non-consolidated) balance sheet and income statement. A loss is shown with a minus sign.

Financial ratios for 2025

Return on equity (ROE)
-0.9 %
Net profit / equity
Return on assets (ROA)
-0.4 %
Net profit / assets
Equity ratio
42.6 %
Equity / assets
Debt ratio
57.4 %
Liabilities / assets
Current ratio
0.16
Current assets / current liabilities

Annual reports

PDFs from e-Äriregister
Annual reports
Year Period Filed Report Documents
2025 1 Jan 2025 – 31 Dec 2025 17 Jun 2026 Company’s own e-Äriregister
2024 1 Jan 2024 – 31 Dec 2024 28 Jun 2025 Company’s own e-Äriregister
2023 1 Jan 2023 – 31 Dec 2023 27 Jun 2024 Company’s own e-Äriregister
2022 1 Jan 2022 – 31 Dec 2022 30 Jun 2023 Company’s own e-Äriregister
2021 1 Jan 2021 – 31 Dec 2021 30 Jun 2022 Company’s own e-Äriregister
2020 1 Jan 2020 – 31 Dec 2020 30 Jun 2021 Company’s own e-Äriregister
2019 1 Jan 2019 – 31 Dec 2019 4 Jan 2021 Company’s own e-Äriregister

Board

  • Henry Aljand
    Board member · since 17 May 2017
  • Toomas Neuman
    Board member · since 17 May 2017
  • Nasdaq CSD SE
    Keeper of the share register · since 9 Jul 2018

Right of representation

Any member of the management board may represent the private limited company in all transactions.

Owners

Beneficial owners

Founders and other persons

shared board members, owners or beneficial owners

Activities (EMTAK)

  • 72111Research and experimental development on biotechnology Main
Rulings
Number, date Title Deadline State Document
Ä 50057450 / 20
31 Jan 2022
Amendment entry In force
31 Jan 2022
PDF
Ä 50057450 / 19
6 Aug 2020
Amendment entry In force
6 Aug 2020
PDF
Ä 50057450 / 18
13 Jul 2020
Amendment entry In force
13 Jul 2020
PDF
Ä 50057450 / 17
5 Apr 2019
Amendment entry In force
5 Apr 2019
PDF
Ä 50057450 / M4
4 Apr 2019
Ruling to eliminate deficiencies 4 May 2019 Deficiencies eliminated
5 Apr 2019
PDF
Ä 50057450 / 16
1 Mar 2019
Amendment entry In force
1 Mar 2019
PDF
Ä 50057450 / M3
27 Feb 2019
Ruling to eliminate deficiencies 13 Mar 2019 Deficiencies eliminated
28 Feb 2019
PDF
Ä 50057450 / 15
12 Feb 2019
Amendment under Commercial Code § 525 (2) In force
12 Feb 2019
PDF
Ä 50057450 / 14
3 Dec 2018
Amendment entry In force
3 Dec 2018
PDF
Ä 50057450 / M2
29 Nov 2018
Ruling to eliminate deficiencies 19 Dec 2018 Deficiencies eliminated
3 Dec 2018
PDF
Ä 50057450 / 9
9 Jul 2018
Amendment entry In force
9 Jul 2018
PDF
Ä 50057450 / 8
9 Jul 2018
Amendment entry In force
9 Jul 2018
PDF
Ä 50057450 / 7
9 Jul 2018
Amendment entry In force
9 Jul 2018
PDF
Ä 50057450 / 13
9 Jul 2018
Amendment entry In force
9 Jul 2018
PDF
Ä 50057450 / 12
9 Jul 2018
Amendment entry In force
9 Jul 2018
PDF
Ä 50057450 / 11
9 Jul 2018
Amendment entry In force
9 Jul 2018
PDF
Ä 50057450 / 10
9 Jul 2018
Amendment entry In force
9 Jul 2018
PDF
Ä 50057450 / 6
8 Jul 2018
Amendment entry In force
8 Jul 2018
PDF
Ä 50057450 / 5
7 Jul 2018
Amendment entry In force
7 Jul 2018
PDF
Ä 50057450 / 4
19 Jan 2018
Amendment entry In force
19 Jan 2018
PDF
Ä 50057450 / 3
13 Dec 2017
Amendment entry In force
13 Dec 2017
PDF
Ä 50057450 / 2
8 Jun 2017
Amendment entry In force
8 Jun 2017
PDF
Ä 50057450 / M1
2 Jun 2017
Ruling to eliminate deficiencies 17 Jun 2017 Deficiencies eliminated
2 Jun 2017
PDF
Ä 50057450
17 May 2017
First entry In force
17 May 2017
PDF

Sources: e-Äriregister and EMTA. Data updated 31 Oct 2026. Open at the source ↗ · Report an error in the data